Chemical Inhibitors to RAS Oncoproteins
Around one in every five human cancers have at least one form of RAS mutation (K-RAS, H-RAS, and N-RAS), making RAS the most frequently mutated gene family in human cancers. Historically, these elusive RAS proteins have been called "undruggable", until a recent breakthrough from AmGen with the FDA’s approval of the anti-cancer drug sotorasib which targets a specific mutation, G12C, in the protein K-RAS.
Not surprisingly, there has been significant activity in this space recently and CAS provides a unique view into this landscape of emerging science in our latest whitepaper - "Chemical Inhibitors to RAS Oncoproteins: Current Landscape and Future Opportunities".
Complete the form below to download the whitepaper.
Read the related CAS Blog - "Emerging trends in targeting "undruggable" RAS proteins for cancer treatment"